Evidence map›Paper›PMID 34207455›Full record

ArticleNanomaterials (Basel, Switzerland)2021

Spiky Gold Nanoparticles for the Photothermal Eradication of Colon Cancer Cells.

Paolo Emidio Costantini, Matteo Di Giosia, Luca Ulfo, Annapaola Petrosino, Roberto Saporetti, Carmela Fimognari, Pier Paolo Pompa, Alberto Danielli, Eleonora Turrini, Luca Boselli and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Paolo Emidio CostantiniDipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.ORCID 0000-0003-1597-6404
Matteo Di GiosiaDipartimento di Chimica "Giacomo Ciamician", Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy.ORCID 0000-0003-3494-298X
Luca UlfoDipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-4438-2608
Annapaola PetrosinoDipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.
Roberto SaporettiDipartimento di Chimica "Giacomo Ciamician", Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy.ORCID 0000-0002-8558-7191
Carmela FimognariDipartimento di Scienze per la Qualità della Vita, Alma Mater Studiorum-Università di Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.ORCID 0000-0002-2461-8214
Pier Paolo PompaNanobiointeractions and Nanodiagnostics, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy.ORCID 0000-0001-7549-0612
Alberto DanielliDipartimento di Farmacia e Biotecnologie, Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 3, 40126 Bologna, Italy.
Eleonora TurriniDipartimento di Scienze per la Qualità della Vita, Alma Mater Studiorum-Università di Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.ORCID 0000-0003-4743-1126
Luca BoselliNanobiointeractions and Nanodiagnostics, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy.ORCID 0000-0002-2732-5484
Matteo CalvaresiDipartimento di Chimica "Giacomo Ciamician", Alma Mater Studiorum-Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy.ORCID 0000-0002-9583-2146
University of Bologna · ITItalian Institute of Technology · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 22318Associazione Italiana per la Ricerca sul Cancro 22894
6 · The paper itself

Abstract

Colorectal cancer (CRC) is a widespread and lethal disease. Relapses of the disease and metastasis are very common in instances of CRC, so adjuvant therapies have a crucial role in its treatment. Systemic toxic effects and the development of resistance during therapy limit the long-term efficacy of existing adjuvant therapeutic approaches. Consequently, the search for alternative strategies is necessary. Photothermal therapy (PTT) represents an innovative treatment for cancer with great potential. Here, we synthesize branched gold nanoparticles (BGNPs) as attractive agents for the photothermal eradication of colon cancer cells. By controlling the NP growth process, large absorption in the first NIR biological window was obtained. The FBS dispersed BGNPs are stable in physiological-like environments and show an extremely efficient light-to-heat conversion capability when irradiated with an 808-nm laser. Sequential cycles of heating and cooling do not affect the BGNP stability. The uptake of BGNPs in colon cancer cells was confirmed using flow cytometry and confocal microscopy, exploiting their intrinsic optical properties. In dark conditions, BGNPs are fully biocompatible and do not compromise cell viability, while an almost complete eradication of colon cancer cells was observed upon incubation with BGNPs and irradiation with an 808-nm laser source. The PTT treatment is characterized by an extremely rapid onset of action that leads to cell membrane rupture by induced hyperthermia, which is the trigger that promotes cancer cell death.

Indexed as

colon cancer cellsgold nanoparticlesNIR triggeringphototheranosticsphotothermal therapyspiky nanoparticles

Identifiers

PMID34207455
PMCPMC8233824
OpenAlexW3176005990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.